Insider · CIK 0001333268
William B. Horne
Files at GPUS (Ault Alliance, Inc.), ALZN (Alzamend Neuro, Inc.). First filing Jan 2, 2025, latest Sep 30, 2026.
In brief
William B. Horne files SEC Form 4 as director and CEO at GPUS (Ault Alliance, Inc.), and also at ALZN (Alzamend Neuro, Inc.). Since Jan 2, 2025, William B. Horne has reported 10 open-market buys worth $244k and 2 open-market sells worth $7,069, the latest filed on Sep 30, 2026.
After William B. Horne's past buys, the stock trailed the S&P 500 by a median 89.5% over six months (n = 3), and 0% of those buys were ahead of the index at six months. InsiderTell labels that a negative record.
The newest scored trade: bought $16k of GPUS on Sep 30, 2026, filed Sep 30, 2026, scored 62 (notable). In the last 12 months: 7 buys worth $231k and 1 sell worth $7,059.
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
GPUS: Ault Alliance, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
ALZN: Alzamend Neuro, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 62Notable | Ault Alliance, Inc. | $16k 100,000 shares | +25% | 0% from low-95% from high | |
| 62Notable | Ault Alliance, Inc. | $17k 100,000 shares | +33% | 0% from low-95% from high | |
| 69Notable | Ault Alliance, Inc. | $18k 1,000 shares | +20% | 0% from low-94% from high | |
| 73Notable | Ault Alliance, Inc. | $31k 160,000 shares | +114% | 0% from low-94% from high | |
| 68Notable | Ault Alliance, Inc. | $20k 100,000 shares | +250% | 0% from low-94% from high | |
| 59Moderate | Ault Alliance, Inc. | $95k 5,000 shares | - | +33% from low-89% from high | |
| 55Moderate | Ault Alliance, Inc. | $34k 200,000 shares | - | +42% from low-96% from high | |
| 43Moderate | Alzamend Neuro, Inc. | $7,059 3,333 shares | -100% | +8% from low-82% from high | |
| 38Weak | Alzamend Neuro, Inc. | $3,285 3,334 shares | +13% | - | |
| 41Moderate | Alzamend Neuro, Inc. | $4,892 5,000 shares | +23% | - | |
| 36Weak | Alzamend Neuro, Inc. | $4,852 5,000 shares | +30% | - | |
| 45Moderate | GPUSsell Ault Alliance, Inc. | $10 2 shares | -100% | +3% from low-39% from high |
Transactions
Every row this insider has filed, 16 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | GPUS Ault Alliance, Inc. | POpen-market purchase Class A Common Stock | +100,000 | $0.16 | $16k | 500,000 | 13 d ago |
| Sep 29, 2026 | GPUS Ault Alliance, Inc. | POpen-market purchase Class A Common Stock | +100,000 | $0.17 | $17k | 400,000 | 14 d ago |
| Sep 16, 2026 | GPUS Ault Alliance, Inc. | POpen-market purchase 13% Series D Cumulative Redeemable Perpetual Preferred Stock | +1,000 | $18.00 | $18k | 6,000 | 25 d ago |
| Sep 4, 2026 | GPUS Ault Alliance, Inc. | POpen-market purchase Class A Common Stock | +100,000 | $0.20 | $20k | 240,000 | 35 d ago |
| Sep 8, 2026 | GPUS Ault Alliance, Inc. | POpen-market purchase Class A Common Stock | +60,000 | $0.19 | $11k | 300,000 | 35 d ago |
| Sep 2, 2026 | GPUS Ault Alliance, Inc. | POpen-market purchase Class A Common Stock | +100,000 | $0.20 | $20k | 140,000 | 41 d ago |
| Jun 29, 2026 | GPUS Ault Alliance, Inc. | POpen-market purchase 13% Series D Cumulative Redeemable Perpetual Preferred Stock | +5,000 | $19.00 | $95k | 5,000 | Jul 1, 2026 |
| Jun 11, 2026 | GPUS Ault Alliance, Inc. | POpen-market purchase Class A Common Stock | +200,000 | $0.17 | $34k | 200,000 | Jun 12, 2026 |
| May 6, 2026 | GPUS Ault Alliance, Inc. | AGrant or award Stock Options (Right to Buy)derivative | +2,000,000 | $0.00 | $0 | 2,000,000 | May 8, 2026 |
| Dec 19, 2025 | ALZN Alzamend Neuro, Inc. | SOpen-market sale Common Stock | -3,333 | $2.12 | $7,059 | 0 | Dec 23, 2025 |
| Mar 26, 2025 | ALZN Alzamend Neuro, Inc. | POpen-market purchase Common Stock | +3,334 | $0.99 | $3,285 | 30,000 | Mar 27, 2025 |
| Mar 20, 2025 | ALZN Alzamend Neuro, Inc. | POpen-market purchase Common Stock | +5,000 | $0.98 | $4,892 | 26,666 | Mar 20, 2025 |
| Mar 18, 2025 | ALZN Alzamend Neuro, Inc. | MOption exercise Common Stock | +10,000 | $0.06 | $600 | 16,666 | Mar 19, 2025 |
| Mar 18, 2025 | ALZN Alzamend Neuro, Inc. | POpen-market purchase Common Stock | +5,000 | $0.97 | $4,852 | 21,666 | Mar 19, 2025 |
| Mar 18, 2025 | ALZN Alzamend Neuro, Inc. | MOption exercise Stock Options (Right to Buy)derivative | -10,000 | $0.00 | $0 | 0 | Mar 19, 2025 |
| Dec 30, 2024 | GPUS Ault Alliance, Inc. | SOpen-market sale Common Stock | -2 | $5.21 | $10 | 0 | Jan 2, 2025 |
Questions about William B. Horne
Answered from the filings on this page, as of the latest one.
Is William B. Horne buying or selling?
In the last 12 months William B. Horne reported 7 open-market buys worth $231k and 1 open-market sell worth $7,059 on SEC Form 4; the latest was bought $16k of GPUS on Sep 30, 2026. Grants, option exercises and tax withholding are not counted.
How did William B. Horne's past buys perform?
Measured from the first close after each filing, the stock trailed the S&P 500 by a median 89.5% over six months across 3 past buys, with 0% ahead of the index. Past results describe what happened; they do not predict the next trade.
Where does William B. Horne file Form 4?
William B. Horne has filed Form 4 at GPUS (Ault Alliance, Inc.) as Chief Executive Officer; ALZN (Alzamend Neuro, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.